NASDAQ:PCRX • US6951271005
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PACIRA BIOSCIENCES INC (PCRX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-26 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2026-01-09 | Needham | Maintains | Buy -> Buy |
| 2026-01-09 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-12-09 | Barclays | Initiate | Equal-Weight |
| 2025-11-07 | Truist Securities | Maintains | Buy -> Buy |
| 2025-05-09 | Needham | Maintains | Buy -> Buy |
| 2025-04-08 | Needham | Reiterate | Buy -> Buy |
| 2025-04-08 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-02-28 | Needham | Maintains | Buy -> Buy |
| 2025-02-28 | Barclays | Maintains | Overweight -> Overweight |
| 2025-02-28 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-01-30 | Truist Securities | Upgrade | Sell -> Hold |
| 2025-01-14 | RBC Capital | Reiterate | Sector Perform -> Sector Perform |
| 2025-01-13 | Needham | Maintains | Buy -> Buy |
| 2024-12-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-12 | Barclays | Maintains | Equal-Weight -> Equal-Weight |
| 2024-11-08 | Needham | Reiterate | Buy -> Buy |
| 2024-11-07 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-10-04 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2024-09-24 | Jefferies | Maintains | Buy -> Buy |
| 2024-08-13 | Truist Securities | Downgrade | Buy -> Sell |
| 2024-08-12 | Needham | Maintains | Buy -> Buy |
| 2024-08-12 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2024-08-12 | JP Morgan | Downgrade | Overweight -> Underweight |
| 2024-08-12 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 674.978M 1.23% | 700.966M 3.85% | 726.411M 3.63% | 775.69M 6.78% | 841.95M 8.54% | 956.78M 13.64% | 940.75M -1.68% | 951.25M 1.12% | 979.82M 3.00% | 1.068B 9.00% | 748.37M -29.93% | |
| EBITDA YoY % growth | 166.321M 2.41% | 180.816M 8.72% | 129.701M -28.27% | 182.06M 40.37% | 222.79M 22.37% | 440.13M 97.55% | 286.11M -34.99% | 261.94M -8.45% | N/A | N/A | N/A | |
| EBIT YoY % growth | 90.747M 27.99% | 102.031M 12.43% | 38.678M -62.09% | 172.83M 346.84% | 209.64M 21.30% | 360.88M 72.14% | 265.52M -26.42% | 286.26M 7.81% | 390.9M 36.55% | 242.12M -38.06% | N/A | |
| Operating Margin | 13.44% | 14.56% | 5.32% | 22.28% | 24.90% | 37.72% | 28.22% | 30.09% | 39.90% | 22.67% | N/A | |
| EPS YoY % growth | 2.92 12.74% | 3.21 9.93% | 2.63 -18.07% | 2.70 2.70% | 3.56 31.93% | 4.58 28.41% | 4.36 -4.81% | 4.34 -0.35% | 3.56 -17.98% | 4.36 22.35% | N/A |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.58 -7.17% | 0.72 -2.53% | 0.71 1.04% | 0.68 19.82% | 0.67 17.23% | 0.84 17.09% | 0.89 25.46% | 1.01 48.08% |
| Revenue Q2Q % growth | 177.47M 5.06% | 193.9M 7.07% | 195.76M 9.05% | 209.76M 6.55% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 41.697M 30.22% | 49.074M -16.94% | 46.129M -44.70% | 41.15M -56.49% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 32.997M 204.06% | 44.064M 316.09% | 37.893M 176.03% | 34.425M 867.27% | N/A | N/A | N/A | N/A |
All data in USD
13 analysts have analysed PCRX and the average price target is 29.29 USD. This implies a price increase of 19.5% is expected in the next year compared to the current price of 24.51.
PACIRA BIOSCIENCES INC (PCRX) will report earnings on 2026-04-30, after the market close.
The consensus EPS estimate for the next earnings of PACIRA BIOSCIENCES INC (PCRX) is 0.58 USD and the consensus revenue estimate is 177.47M USD.
The consensus rating for PACIRA BIOSCIENCES INC (PCRX) is 76.9231 / 100 . This indicates that analysts generally have a positive outlook on the stock.